Clinical Trial Update: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of BIA 28-6156 in Parkinson's disease patients with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 28-6156

Snippet

Sponsor: Bial R&D Investments, S.A. | Conditions: Parkinson's Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING